All In Biotech

Drug Trial Radar · NCT07154264

A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10)

A Phase 2 Study of DZD8586 Combination Therapy in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)

Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

66

Planned (sponsor's estimate)

Start

Sep 22, 2025

Primary completion

Dec 2029

Study completion Jan 2030

Sponsor

Lead sponsor
Dizal PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Sep 4, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2 study to investigate the efficacy and safety of DZD8586 in combination in participants with CLL/SLL. This study consists of two parts: Part A is the safety lead-in phase, and Part B is the dose expansion phase.

Conditions

  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Interventions

  • DZD8586Drug

    DZD8586 will be taken orally once daily on days 1-28 of each cycle.

  • VenetoclaxDrug

    Venetoclax will be taken orally once daily on days 1-28 starting from cycle 4 day 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Incidence of Adverse EventsTime frame: 30 days after the last dose
  2. Part B: 2-year progression free survival (PFS) rate assessed by investigatorTime frame: Approximately 5 years

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Anhui Provincial Cancer Hospital

    Hefei, Anhui, China · Recruiting

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, Guangdong, China · Recruiting

  • Nanfang Hospital, Southern Medical University

    Guangzhou, Guangdong, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Recruiting

  • Yichang Central People's Hospital

    Yichang, Hubei, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

  • The First People's Hospital of Changzhou

    Changzhou, Jiangsu, China · Recruiting

  • Affiliated Hospital of Nantong University

    Nantong, Jiangsu, China · Recruiting

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China · Recruiting

  • The First Bethune Hospital of Jilin University

    Changchun, Jilin, China · Recruiting

  • Shengjing Hospital of China Medical University

    Shenyang, Liaoning, China · Not yet recruiting

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China · Recruiting

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.